C

Celcuity
D

CELC

13.160
USD
0.03
(0.23%)
مغلق
حجم التداول
8,647
الربح لكل سهم
-3
العائد الربحي
-
P/E
-5
حجم السوق
488,624,957
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ADPT
    -0.06500
    (-0.78%)
    8.27000 USD
    A
    ALVR
    -0.54000
    (-5.49%)
    9.30000 USD
    C
    CELC
    0.030
    (0.23%)
    13.160 USD
    D
    DNLI
    -0.840
    (-3.89%)
    20.740 USD
    F
    FGEN
    -0.09040
    (-11.70%)
    0.68200 USD
    I
    IMVT
    0.800
    (3.92%)
    21.230 USD
    N
    NERV
    0.06000
    (3.30%)
    1.88000 USD
    P
    PLRX
    0.08000
    (2.66%)
    3.08500 USD
    T
    TNXP
    -0.53000
    (-5.48%)
    9.15000 USD
    V
    VCEL
    -2.230
    (-4.11%)
    52.060 USD
    المزيد
الأخبار
المقالات

العنوان: Celcuity

القطاع: Healthcare
الصناعة: Biotechnology
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic propertiesare highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.